|3.81||+0.1100||+2.97%||Vol 1.69M||1Y Perf 14.55%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||5.13||Analyst Rating||Strong Buy 1.00|
|Potential %||34.65||Finscreener Ranking||★★★+ 50.99|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||★ 39.53|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||★ 37.09|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Price Range Ratio 52W %||50.73||Earnings Rating||Buy|
|Market Cap||860.94M||Earnings Date||8th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.01|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.16M|
|Avg. Monthly Volume||1.87M|
|Avg. Quarterly Volume||1.75M|
ADMA Biologics Inc (NASDAQ: ADMA) stock closed at 3.81 per share at the end of the most recent trading day (a 2.97% change compared to the prior day closing price) with a volume of 1.69M shares and market capitalization of 860.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 314 people. ADMA Biologics Inc CEO is Adam S. Grossman.
The one-year performance of ADMA Biologics Inc stock is 14.55%, while year-to-date (YTD) performance is -1.8%. ADMA stock has a five-year performance of -27.7%. Its 52-week range is between 2.945 and 4.65, which gives ADMA stock a 52-week price range ratio of 50.73%
ADMA Biologics Inc currently has a PE ratio of -10.40, a price-to-book (PB) ratio of 7.99, a price-to-sale (PS) ratio of 7.45, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -26.08%, a ROC of -23.38% and a ROE of -69.23%. The company’s profit margin is -51.56%, its EBITDA margin is -35.80%, and its revenue ttm is $104.10 Million , which makes it $0.47 revenue per share.
Of the last four earnings reports from ADMA Biologics Inc, there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.01 for the next earnings report. ADMA Biologics Inc’s next earnings report date is -.
The consensus rating of Wall Street analysts for ADMA Biologics Inc is Strong Buy (1), with a target price of $5.13, which is +34.65% compared to the current price. The earnings rating for ADMA Biologics Inc stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ADMA Biologics Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ADMA Biologics Inc has a Buy technical analysis rating based on Technical Indicators (ADX : 19.27, ATR14 : 0.15, CCI20 : -16.43, Chaikin Money Flow : -0.08, MACD : 0.08, Money Flow Index : 52.70, ROC : 1.87, RSI : 55.47, STOCH (14,3) : 39.53, STOCH RSI : 0.36, UO : 38.02, Williams %R : -60.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ADMA Biologics Inc in the last 12-months were: Adam S. .Grossman (Option Excercise at a value of $4 721 099), Adam S. .Grossman (Sold 760 472 shares of value $3 355 042 ), Brian Lenz (Option Excercise at a value of $1 904 948), Brian Lenz (Sold 389 762 shares of value $1 766 178 ), Grossman Jerrold (Buy at a value of $482 300), Young T. Kwon (Buy at a value of $97 500)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.